{
    "organizations": [],
    "uuid": "630f1f1292f666315116fbdeb6603df1acd2c710",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/merck-co-study/mercks-keytruda-meets-main-goal-in-lung-cancer-trial-idUSL3N1RM382",
    "ord_in_thread": 0,
    "title": "Merck's Keytruda meets main goal in lung cancer trial",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 9 (Reuters) - Merck & Co said on Monday a late-stage trial testing its blockbuster cancer drug, Keytruda, met the main goal of helping previously untreated lung cancer patients live longer.\nThe trial tested Keytruda as a monotherapy to treat non-small cell lung cancer.\nThe companyâ€™s shares rose 2.6 percent to $54.75 in premarket trading. (Reporting by Tamara Mathias in Bengaluru; Editing by Sriraj Kalluvila)\n ",
    "published": "2018-04-09T19:05:00.000+03:00",
    "crawled": "2018-04-10T13:00:53.043+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "merck",
        "co",
        "said",
        "monday",
        "trial",
        "testing",
        "blockbuster",
        "cancer",
        "drug",
        "keytruda",
        "met",
        "main",
        "goal",
        "helping",
        "previously",
        "untreated",
        "lung",
        "cancer",
        "patient",
        "live",
        "longer",
        "trial",
        "tested",
        "keytruda",
        "monotherapy",
        "treat",
        "cell",
        "lung",
        "cancer",
        "company",
        "share",
        "rose",
        "percent",
        "premarket",
        "trading",
        "reporting",
        "tamara",
        "mathias",
        "bengaluru",
        "editing",
        "sriraj",
        "kalluvila"
    ]
}